Idursulfase beta, an original drug for the treatment of Hunter syndrome, a rare disease, was registered in Russia by Nanolek, a biopharmaceutical company, in cooperation with Green Cross, a South Korean company.
The common market information system, that allows pharmaceutical companies to submit their drug registration dossiers under two procedures in accordance with EAEU rules, is expected to start operating in Q1 2018.
The conference was organized under the aegis of the pharmaceutical company Roche Georgia and is connected to the introduction of the innovative drug Ocrevus (Ocrelizumab) onto the Georgian pharmaceutical market.
The Russian Ministry of Health has registered BCD-055, the first Russian-made biosimilar of infliximab developed by BIOCAD, a biotech company. BIOCAD was developing the local biosimilar of infliximab since 2013.